Biosimilar monoclonal antibodies market seen reaching $14.58 billion by 2030
The biosimilar monoclonal antibodies market is projected to grow from $11.29 billion in 2026 to $14.58 billion by 2030, according to The Business Research Company. Demand for lower-cost biologic treatments, more biosimilar approvals and expanding use in cancer and autoimmune care are driving the outlook.
Why it matters: - Biosimilar monoclonal antibodies are a lower-cost alternative to original biologic drugs, which could expand access to treatments for cancer, rheumatoid arthritis and other autoimmune conditions. - The market’s projected growth signals continued pressure on healthcare systems to balance biologic innovation with affordability. - The category is also becoming more important as more major monoclonal antibody drugs lose patent protection.
What happened: - The Business Research Company projected the global biosimilar monoclonal antibodies market will rise from $11.29 billion in 2026 to $14.58 billion by 2030. - The forecast implies a 6.6% compound annual growth rate through 2030. - The company also estimated the market grew from $10.64 billion in 2025 to $11.29 billion in 2026, a 6.2% CAGR. - The report is titled Biosimilar Monoclonal Antibodies Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - A free sample of the report is available here.
The details: - The report said past growth was driven by the high cost of original biologics, rising chronic and autoimmune disease prevalence, patent expirations on major monoclonal antibody drugs, higher healthcare spending and clearer regulatory pathways for biosimilars. - Future growth is expected to come from an expanding biosimilar pipeline, broader use of affordable biologic alternatives, more regulatory approvals in emerging economies, better biopharmaceutical manufacturing and stronger government support. - The report pointed to wider acceptance of cost-effective biosimilar monoclonal antibodies, more use in cancer and autoimmune disease treatment, stronger physician and patient confidence and greater efforts to improve global access to biologic therapies. - Biosimilar monoclonal antibodies are complex biosimilars designed to mimic original biologic drugs and are used to target diseased cells or immune responses. - The therapies are used in serious conditions including cancer and rheumatoid arthritis. - The report said the global autoimmune disease burden is a key growth driver because these conditions arise when the immune system attacks the body’s own tissues. - Environmental triggers such as pollution and chemical exposure can contribute to autoimmune disorders by disrupting normal immune function. - Arthritis Australia projected in February 2024 that rheumatoid arthritis cases in Australia will grow from 574,273 in 2025 to nearly 760,000 by 2040. - The Australia projection breaks down to 212,136 males and 362,137 females in 2025, rising to 280,040 males and 479,828 females by 2040.
Between the lines: - The forecast suggests biosimilars are moving from a niche cost-saving option to a more central part of oncology and autoimmune care. - North America’s lead in 2025 reflects mature healthcare spending and regulation, but faster gains may come from emerging economies if approval processes keep improving. - The growth story depends less on one product cycle and more on a broader shift in prescribing, manufacturing and payer acceptance.
What's next: - The report expects more biosimilar approvals, more pipeline activity and greater adoption in cost-sensitive markets through 2030. - The Business Research Company said its 2026 report set includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables. - The full report is available here. - North America remained the largest regional market in 2025, with coverage also spanning Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.
The bottom line: - Biosimilar monoclonal antibodies are on track for steady global expansion as payers, providers and regulators push for cheaper biologic options without sacrificing treatment access.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Asia News Digest
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.